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ABSTRACT
Objectives: Migraine is often perceived as a low-impact condition that
imposes a limited burden to society and the health-care system. This study
reviews the current understanding of the burden of migraine in the U.S.,
the history of economic understanding of migraine treatment and identiﬁes
emergent trends for future studies evaluating clinical and economic out-
comes of migraine treatment.
Methods: This study traced the history of economic articles published on
migraine by performing a literature search using PubMed MEDLINE
database and ancestral searches of relevant articles. The intention was not
to provide an exhaustive review of every article or adjudicate between
studies with different ﬁndings.
Results: Migraine affects millions of individuals worldwide, generally
during the most productive years of a person’s life. Studies show that
migraineurs are underdiagnosed, undertreated, and experience substantial
decreases in functioning and productivity, which in turn translates into
diminished quality of life for individuals, and ﬁnancial burdens to both
health-care systems and employers. Economic evaluations of migraine
therapies have evolved with new clinical developments beginning with
cognitive-behavioral therapy, introduction of triptans, concern over medi-
cation overuse, and emergence of migraine prophylaxis. Now recent clini-
cal studies suggest that migraine may be a progressive disease with
cardiovascular, cerebrovascular, and long-term neurologic effects.
Conclusions: Migraine imposes a substantial burden on patients, families,
employers and societies. The economic standards by which migraine and
treatment are evaluated have evolved in response to clinical developments.
Emerging evidence suggests that migraine is a chronic and progressive
disease. If conﬁrmed, approaches to acute and prophylactic treatments
and economic evaluations of migraine treatment may require major
reconsideration.
Keywords: burden of illness, economic, migraine, United States.
Introduction
Migraine is often perceived as a low-impact condition that
imposes a limited burden to society and the health-care system.
This misperception persists in part because the disorder is epi-
sodic, does not shorten life expectancy, and rarely causes long-
term physical disability. Because it is underdiagnosed and
undercoded, analyses of claims data underestimate prevalence
[1–3]. Although the percentage of adults with migraine is mark-
edly less than that of tension-type headache (11% vs. 42%,
respectively) [4], migraine nevertheless affects millions of indi-
viduals worldwide and signiﬁcantly impairs sufferers’ ability to
function. It is most prevalent between the ages of 25 and 55,
generally the most productive years of a person’s life, generating
substantial lost work time. Quantitative evidence also shows that
migraineurs and other headache sufferers experience substantial
decreases in functioning and productivity, which in turn trans-
lates into signiﬁcant health-related quality of life (HRQoL)
burdens on individuals and ﬁnancial burdens to employers [5–7].
Furthermore, emerging evidence indicates that migraine is
sometimes a progressive disease with cardiovascular, cerebrovas-
cular, and long-term neurologic effects [8,9]. If this is the case, a
rethinking of approaches to both acute and preventive therapy, as
well as a reconsideration of economic evaluations of the utility of
migraine treatment, is required. As with most other diseases, the
understanding of and research about migraine has changed sig-
niﬁcantly, as shown in Table 1. The changes in efﬁcacy of treat-
ment with the introduction of triptans generated a relatively large
body of literature on the economics of migraine and migraine
treatments. Now, new developments in the understanding of
migraine will generate new studies on the economics of migraine
prevention, and our understanding of the cost-effectiveness of
prophylactic treatments will continue to develop as the long-term
clinical consequences of migraine are studied.
In this article, we ﬁrst present a review of our current under-
standing of the burden of migraine in the United States, and then
turn to the history of our economic understanding of the treat-
ment of migraine.
Methods
To accomplish our goal, we traced the history of economic
articles published on migraine by performing a literature search
using the PubMed MEDLINE database, as well as ancestral
searches of relevant articles. The ﬁrst article on the burden of
migraine in the United States appeared in 1994 [10]. Articles on
the cost of the ﬁrst triptan began appearing in 1992 [11], with
the ﬁrst economic comparison of sumatriptan with nontriptan
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treatment appearing in Clinical Therapeutics in 1994 [12]. This
was followed by tens of articles, published through the present,
reporting different studies of the impact of triptans on direct and
indirect costs and patient-reported outcomes. In this review, we
highlight the issues raised by this now very large body of litera-
ture by focusing on a subset of key articles. Our intention is to
highlight the change in focus over time rather than provide an
exhaustive review of every article or adjudicate between studies
with different ﬁndings.
Current Knowledge of Burden of Migraine
Migraine Epidemiology: Incidence and Prevalence
Estimating migraine incidence within a given population is chal-
lenging. Because of the episodic nature of the migraine disorder,
and because migraine is frequently underreported and under-
treated, it can be difﬁcult to pinpoint the age of migraine onset or
to retrospectively assess its incidence. As a result, migraine inci-
dence has been assessed in few longitudinal studies and research
evaluating migraine incidence is less common than prevalence
studies [13,14].
Historically, it has also been challenging to quantify
migraine prevalence. This has been because of variations in
methodologies employed to obtain data, a lack of universal
clinical standards for migraine diagnosis, and variations in age
and sex distributions in evaluated populations [15,16]. The
International Classiﬁcation of Headache Disorders (ICHD) ini-
tially published in 1988 (ICHD-1) and revised in 2005 (ICHD-
2), has standardized migraine diagnosis and provided a
foundation for a series of community-based studies that have
enabled us to obtain a more encompassing picture of the disor-
der’s incidence and prevalence [17]. Linet and colleagues con-
ducted a study of migraine with and without preceding visual
aura through a Washington County, Maryland telephone survey
of individuals aged 12 to 29 years (n = 10,169). A total of 392
men and 1018 women reported a history of migraine [18]. They
found that migraine occurs more frequently in women com-
pared with men, presents earlier in life in males than in females,
and that migraine with aura presents at an earlier age than
migraine without aura.
The 1989 American Migraine Study I (AMS I) concluded that
approximately 23.6 million Americans, including 17.6% of
women and 5.7% of men, suffered from migraine disorder [19].
The American Migraine Study II (AMS II), conducted in 1999,
found that the number of migraineurs had grown to 27.9 million
in 1999 commensurate with the corresponding increase in US
population [20]. The 1-year prevalence of migraine based on
data collected in 1999 in AMS II was 18.2% among females and
6.5% among males. The American Migraine Prevalence and
Prevention (AMPP) study in 2004 found that the unadjusted
1-year prevalence was 11.7% (17.1% in females and 5.6% in
males) [21]. Nevertheless, as shown in Figure 1, only a minority
of those meeting the ICHD-2 criteria for migraine reported
having received a diagnosis of migraine.
Table 1 History of migraine treatment and clinical and economic understanding
Disease model Years Treatment Burden of illness Beneﬁt of treatment
Acute pain disorder Prior to 1990 Analgesics Lost time during the acute attack Sedation often offset pain relief
Acute neurovascular
disorder
1991– Triptans Lost time during the acute attack Productivity gains during attacks
CDEM 1998– Triptans
Preventives
Lost time during attacks
Disrupted HRQoL between attacks
Productivity gains during attacks
Improved HRQoL
Chronic episodic and
sometime chronic
progressive disorder
2006– Triptans
Preventives
Intervention to prevent
progression
Lost time during attacks
Disrupted HRQoL between attacks
Consequences of progressive disease
Long-term brain impact
Productivity gains during attacks
Improved HRQoL
Value of slowing or halting disease
progression
CDEM, chronic disorder with episodic manifestations; HRQoL, health-related quality of life.
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Figure 1 Prevalence of migraine and diagnosis of migraine: 1989, 1999 and
2004. Stewart 1992 represents diagnoses for 1989 (males, n = 9,660; females,
n = 10,808), Lipton 2001 represents diagnoses for 1999 (males, n = 14,260;
females, n = 15,467), and Lipton 2007 represents diagnoses for 2004 (males,
n = 77,185; females, n = 85,571). Sources: Stewart et al. 1992 [19], Lipton et al.
2001 [20] and Lipton et al. 2007 [23]. ICHD, International Classiﬁcation of
Headache Disorders.
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Studies of consultation patterns show that in any given year,
48% of migraine sufferers will see a doctor for their headaches.
These current consulters have more frequent and more severe
headaches than nonconsulters [22]. As a consequence, prevalence
estimates of the burden of migraine derived from health-care
settings are prone to at least two forms of bias. Speciﬁcally, these
studies underestimate prevalence (as many people remain undi-
agnosed) and overestimate disease severity (as consulters have
more severe disease).
Prevalence related to age and sex. As noted above, during the
adult years, migraine affects signiﬁcantly more women than men.
Migraine’s impact is felt most strongly between the ages of 25
and 50 years, with its highest prevalence between the ages of 30
and 49 years. Peak prevalence occurs at approximately 40 years
of age (Fig. 2). This is a particularly stressful burden, because for
most people, these represent the most productive years of life
[20,23,24]. To our knowledge, no studies have been published
in the United States on the relationship between aging and
migraine. Nevertheless, ﬁndings from European long-term
follow-up studies demonstrate that migraine continues to be
burdensome with aging. Although researchers in Denmark have
found that migraine incidence remits with advancing age [25],
relief from migraine does not always accompany aging; a 40-year
longitudinal study conducted in Sweden found that more than
50% of migraine sufferers who had their ﬁrst attacks when
young were still having migraines at age 50 [26].
Migraine Management: Underdiagnosis
and Undertreatment
Numerous studies report that the majority of migraine sufferers
have either never been diagnosed and/or have not received
adequate treatment for the disorder. In a follow-up analysis of
the AMS I, Lipton and colleagues estimated that only 66% of
migraine sufferers had ever consulted a doctor for headache [27].
Consultation rates were higher for females and for patients who
experienced severe migraine-related disability, and tended to
increase with increasing age [15,27]. Nonetheless, even among
patients who had consulted physicians, only 65.7% of female
and 57.9% of male migraineurs had been properly diagnosed
[27].
Because safe and effective treatment is available for migraine,
ensuring that migraineurs receive appropriate therapy is beneﬁ-
cial for individual sufferers, the health-care system, and society.
Nevertheless, in a national sampling of the US population
(n = 20,468), Celentano and colleagues found that only 28% of
male and 40% of female US migraineurs used acute prescription
migraine medication [28]. Among those with a physician diag-
nosis of migraine, only 49% of men and 64% of women reported
current treatment with prescription medication [28]. This was
the same rate found in the 2004 AMPP study. Just 56.2% of
those with migraine had ever received a medical diagnosis, and
49% of migraineurs reported using over the counter (OTC)
medications only to treat their migraine attacks [21,23]. Along
the same lines, a large-scale US community survey conducted by
Stewart and colleagues found that the majority of migraine suf-
ferers who reported more than three headaches each month
and/or signiﬁcant disability associated with their headaches did
not take acute prescription medication [15].
As with acute medication, prophylactic medication for
migraine is also underused. The 2004 AMPP study found that
over one-third (38.8%) of patients met the study guidelines for
being offered (25.7%) or considered for (13.1%) prophylactic
medication, but only 12.4% indicated that they were taking a
migraine preventive medication [23]. Nevertheless, 17.2% were
using medications that could be used to prevent migraine for
other medical reasons (for example, a beta-blocker for hyperten-
sion) [21].
In some cases, a self-management approach to migraine using
OTC therapy or other modalities is appropriate—for example,
when patients only experience infrequent, mild migraine attacks.
Nevertheless, Lipton and colleagues found that 61% of noncon-
sulters reported severe or very severe pain, while 67% reported
severe disability or the need for bed rest with their headaches
[27,29]. This makes it clear that in many cases, self-management
is not efﬁcacious.
Migraine Human Impact: Quality of Life
The concept of quality of life (QoL) proposes that health is deﬁned
not only by the absence of disease, but by the presence of physical,
mental, and social well-being. HRQoL is a subset of overall QoL
that encompasses individuals’ health state, functional status (both
physical and mental), and overall well-being [30].
A body of research now demonstrates that migraine poses a
substantial and unique HRQoL burden on its sufferers. Patients
with migraine experience not only diminished HRQoL compared
with normal, healthy individuals but also decreased HRQoL
comparable with or in some cases greater than that experienced
by individuals with more serious diseases. For example, Turner-
Bowker and colleagues conducted a survey by mail and the
Internet to compare the burden of migraine with other chronic
conditions in 7557 participants using the SF (Short Form)-8
Health Survey, an abbreviated generic survey derived from the
SF-36 Health Survey. Results showed that the health-related
impact of migraine was comparable with that experienced by
patients with congestive heart failure, hypertension, or diabetes
[30].
The effect of migraine on HRQoL was examined in a
population-based study. Lipton and colleagues found that both
the Physical and Mental Component scores of the SF-12 were
reduced in a general sample of the US population with migraine;
this effect was independent of the inﬂuence of depression [31].
Furthermore, migraine has been shown to impact patients’
HRQoL during periods between attacks as a result of apprehen-
sion and worries associated with the anticipation of the next
attack. Migraine patients have reported signiﬁcantly more sleepi-
ness (P = 0.007), less vigor (P < 0.05), and shorter duration of
activity during the afternoon (P = 0.018) and evening (P = 0.006)
compared with patients without migraine, and less than half of
migraine patients return to normal functioning between migraine
attacks [32].
Figure 2 Age-speciﬁc prevalence of migraine by sex. Source: Lipton et al. 2001
[20].
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These studies and others [33] conﬁrm that migraine is a
disabling condition that leads to compromised HRQoL. Never-
theless, as the next section will discuss, the majority of migraine
costs are borne by society and the health-care system in terms of
lost productivity and increased health-care utilization.
The Cost of Migraine
When costs associated with migraine are analyzed, they are
usually categorized as direct and indirect costs. Direct costs are
those related to the use of medical resources, including physician
visits for diagnosis and/or treatment, emergency room (ER)
visits, diagnostic procedures, and medication. Indirect costs are
generally assessed in terms of temporary disability, reduced func-
tionality, lost productivity, and associated costs to employers.
Tables 2 and 3 provide a summary of direct and indirect costs of
migraine published since 2002. As evidenced in Table 2 and 3,
cost and productivity estimates varied widely across the studies
because of methodological differences, such as: overall severity of
disease in population sampled, operational deﬁnition of
migraine, and medications and services included in aggregate
totals.
Direct costs. A few studies have quantiﬁed the overall direct
medical costs associated with migraine. Hu and colleagues sought
to estimate migraine-related costs, from a societal perspective,
using direct medical costs related to inpatient, outpatient, and
prescription drug claims obtained from 1994 MEDSTAT Mar-
ketscan data. Prescription drug claims for ergotamine tartrate
(Ergomar, Ergostat), ergotamine tartrate combinations (Caf-
etrate, Ercaf, Migergot/Migergot-PB, Wigraine, Bel-Phen-Ergot,
Bellergal/Bellergal-S, Phenerbel-S, Cafergot/Cafergot-PB, Ergo-
Caff/Ergo-Caff-PB), dihydroergotoxine (Ergoloid Mesylates),
dihydroergotamine (D.H.E. 45), sumatriptan (Imitrex), and
methysergide (Sansert) were used to determine prescription costs.
Prescription drug costs amounted to $46.2 million in total costs
for males and $254 million in total costs for females. It is impor-
tant to note that Hu et al. captured cost in 1994, when only one
triptan was available in the market. In their ﬁndings, the authors
indicated that annual US migraine-related direct costs were
approximately $1 billion [7]. This estimate is conservative,
because OTC medications, preventative medications, and
nondrug-related interventions were not assessed.
New studies have found higher direct costs, both because of a
more robust methodology and the fact that only one triptan was
available at the time of the Hu study [4,33]. In a 1999–2000
matched comparison of migraineurs and healthy cohorts using
MedStat’sMarketScan Commercial Claims and Encounter (CCE)
and Health and Productivity Management (HPM) databases of
inpatient, outpatient, and prescription drug claims (ergot or
triptan) based on average wholesale price (AWP) for outpatient
drugs and total gross payments to providers for inpatient drugs,
Pesa and Lage found that both adult and childrenmigraineurs had
signiﬁcantly higher total direct medical costs compared with
nonmigraineurs (P < 0.0001). Costs for adults were $7089 for
migraineurs versus $2923 for nonmigraineurs and for children
were $4272 versus $1400 [34]. Barron and colleagues estimated
the cost of treating migraine in the ER using discharge data from
the 2000 National Hospital Ambulatory Medical Care Survey
(NHAMCS) and Medicare reimbursement rates. They estimated
that the cost of a single ER visit was $238.16. Assuming amigraine
prevalence of 9% to 27% and using the proportion of ER visits by
migraineurs based on the discharge data, the researchers estimated
that the annual US costs associatedwith ER visits to treatmigraine
ranged from $646 million to $1.94 billion [35]. A cost analysis Ta
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using a population-based survey showed that the direct total cost
(ER visits, physician visits, hospitalizations) over 6 months were
signiﬁcantly higher for migraineurs compared with nonmi-
graineurs ($522 vs. $415, respectively; P = 0.039) [36]. Another
study by Lafata and colleagues reported that direct costs because
of ER visits, hospitalizations, and prescription drugs were signiﬁ-
cantly higher in patients with migraine compared with nonmi-
graine ($2761 vs. $2064, respectively; P < 0.01) [37]. Etemad and
colleagues estimated the overall direct medical cost of migraine
and also evaluated the impact of prophylaxis. Direct medical costs
included claims for ER visits, hospitalizations, ofﬁce visits, and
migraine speciﬁc medications, such as ergotamine products,
isometheptene combination products, methysergide, sumatriptan,
zolmitriptan, naratriptan, and rizatriptan. The authors reported
the total direct cost to be $989 per migraineur per year. In
addition, prophylaxis resulted in an average cost savings of $550
per migraineur per year in moderate-to-severe migraine patients
[38].
The most recently published study of migraine direct costs
was based on 2004 data from the Thomson-Medstat Commer-
cial Claims and Encounters database. Hawkins and colleagues
found that total costs of pharmacy and medical care were $7007
per patient per year for migraineurs versus $4436 for nonmi-
graineurs. They reported the costs of prescriptions, inpatient,
outpatient, and ER for migraineurs were $1006, $51, $318, and
$67 per patient per year, respectively. The estimated national
direct cost burden of migraine from this study was $11 billion, of
which $4.6 billion was in prescription drugs, $5.2 billion in
outpatient costs, $0.5 billion in ER and $0.7 billion in inpatient
costs [39].
Physician visits make up a large percentage of total migraine-
related direct costs. In a study using 1990 to 1998 NHAMCS
data, Gibbs and colleagues identiﬁed 35.5 million physician visits
for migraine over the study period (14 visits per 1000 persons per
year) [40]. Hu and colleagues estimated that the cost of physician
ofﬁce visits represented 54% and 69% of total migraine-
associated direct costs for women and men, respectively [7].
Historically, a number of conditions have been noted to be
comorbid with migraine, notably psychiatric disorders (anxiety,
depression, panic disorder), epilepsy, asthma, and some congeni-
tal heart defects. Migraine sufferers have increased medical costs
overall compared with others of the same sex and age, even after
considering the cost of speciﬁc migraine treatment. Thus, esti-
mates of the burden of migraine often include the costs of con-
ditions comorbid with it [41]. In 1994, Clouse and Osterhaus
showed in a study of migraine sufferers in a managed health-care
setting that comorbid conditions were responsible for a signiﬁ-
cant percent of the increased costs incurred by the study group
[42]. More recently, Pesa and Lage demonstrated that there is a
signiﬁcant increase in the economic burden of migraine when it is
comorbid with anxiety or depression [34].
Migraine appears to have a direct economic impact on fami-
lies as well. Stang and colleagues quantiﬁed the total family costs
of those with at least one migraineur in the family compared with
matched nonmigraineur families. Direct costs measured were
associated with health-care utilization (outpatient visits, ER
visits, and hospitalizations). They found that the total medical
costs of families with at least one migraineur were 70% greater
than matched nonmigraineur families [43].
Indirect costs. Even though the direct costs of migraine in the
United States are substantial, overall health-care utilization costs
may be underestimated given the existing level of migraine under-
diagnosis and undertreatment [27]. Furthermore, direct medical
costs of migraine are only a fraction of the disease’s overall costTa
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to society. Using 1986 estimates of US median earnings, Oster-
haus and colleagues found that costs to employers because of
reduced productivity and missed workdays ranged from $5.6
billion to $17.2 billion, depending on prevalence [42]. Hu and
colleagues found that indirect costs of migraine in the United
States could be conservatively estimated at $13.3 billion, and
concluded that indirect costs make up approximately 93% of the
total economic burden of migraine. These estimates of indirect
costs were based on missed work days and impaired work per-
formance and did not capture unemployment or underemploy-
ment because of migraines, burden experienced between attacks,
lost home-worker time due for chores, or lost time because of
caring for family members with migraine.
Further, Hu and colleagues found that almost $8 billion of
this $13.3 billion is because of migraine-related missed workdays
[7]. Estimates of actual numbers of lost workdays associated
with migraine vary. For example, Stewart and colleagues asked a
sample of 1663 migraine sufferers to estimate missed workdays
and work-related impairment (presenteeism). Using a formula
calculating lost workday equivalents (LWDE), researchers found
that 51.1% of women and 38.1% of men with migraine experi-
enced six or more LWDEs annually [44]. Other studies have
estimated that migraine sufferers experience the equivalent of 4.2
to 12 lost workdays per year [45,46]. In addition, Gerth and
colleagues found that subjects self-reported being only 46%
effective while working with migraine [47]. These estimates of
the importance of lost workdays and decreased productivity are
conﬁrmed by a 2003 cross-sectional analysis (n = 28,902) apply-
ing data from the American Productivity Audit. In this study,
Stewart and colleagues found that headache-related absenteeism
and reduced work productivity cost approximately $19.6 billion
dollars each year [5]. A recent study by Goetzel and colleagues
compared the percent of daily work time impaired across the top
10 conditions measured by four different instruments. The
average impairment ranged between 5.7% and 17.9% (depend-
ing upon the instrument used), while the range for migraine was
from a low of 8.3% to a high of 28.5% [48].
The most recent study of migraine indirect costs found that a
cohort of migraineurs incurred signiﬁcantly higher indirect costs
in all categories studied, including absence, short-term disability,
and worker’s compensation. Compared with a propensity score-
matched cohort of patients without migraine, the total indirect
costs for migraineurs were $2834 more than for the matched
cohort ($4453 vs. $1619 per year, respectively). The total esti-
mated indirect burden, excluding presenteeism, was $12 billion
[49].
Migraine families experience higher indirect health-care costs
than nonmigraine families. Stang and colleagues quantiﬁed the
indirect burden of migraine by measuring short- and long-term
disability and absenteeism associated with migraine. The study
found that the number of short-term disability days was 2.3
times higher in migraine families compared with matched non-
migraine families. In addition, the employed parent in a migraine
family lost an average of four additional sick days per year, ﬁve
additional short-term disability days, and three additional work-
man’s compensation days compared with parents in nonmigraine
families [43].
Evolution of Economic Evaluations of Migraine
Therapies Following Clinical Developments
As with other disease states, the economic standards by which
migraine and migraine treatments are evaluated have evolved in
response to clinical developments. The following sections discuss
both historic and emergent trends in the economic analysis of
migraine, as well as the clinical developments upon which these
have been based.
The Minimal-Therapist-Contact Approach
Economic considerations associated with migraine received little
attention prior to the development of triptans, the ﬁrst effective
treatment for acute migraine. Prior to the introduction of trip-
tans, ergotamine was the mainstay of acute migraine pharmaco-
logical treatment. To our knowledge, no published economic
evaluations of the ergot alkaloids are available. A few rare excep-
tions exist, most notably studies in the 1980s that examined the
efﬁcacy and cost-effectiveness of the minimal-therapist-contact
approach to migraine, in which the patient was taught cognitive–
behavioral therapy “self-help” techniques in a few sessions, com-
pared with a comparable clinic-based approach. Richardson and
McGrath compared the efﬁcacy of the minimal-therapist-contact
approach with a clinic-based cognitive–behavioral program and
found that the frequency of headache, duration of intensity, and
peak intensity were signiﬁcantly reduced in both groups for up to
6 months [50]. Another study also found that both approaches
resulted in a signiﬁcant reduction in headache frequency, dura-
tion, and peak intensity [51]. In the absence of effective acute
treatments, the minimal-therapist-contact approach was found
to be more cost-effective [50,51].
Early Studies of the Economic Burden of Migraine
Starting in 1992, research on the economic burden of migraine in
the United States began to appear. For example, to assess the
costs associated with migraine, both direct and indirect, Oster-
haus and colleagues surveyed patients who had participated in
clinical trials of an antimigraine compound [52]. Migraine fre-
quency and costs associated with health-care resource use,
decreased productivity, and missed workdays were measured. By
1994, a number of articles had assessed the economic impact of
migraine on both the health-care system and society, and found
that cost-effective interventions could signiﬁcantly reduce the
burden of migraine both for society and individual sufferers [15].
At that time, researchers began to examine medical and phar-
macy claim databases to assess the migraine-related costs asso-
ciated with health-care resource utilization and medication.
Methodologies applied included comparisons of resource use
among migraineurs compared with nonmigraineurs, drug costs
compared with the burden imposed by other resource use, as well
as dollar cost of the burden of migraine. These reviews often
concluded that more data and improved assessments of the asso-
ciated costs and severity of migraine were needed to understand
the true burden of the disease on society [15,42,53,54]. Today,
researchers continue to strive to ﬁnd methodologies that will
fully capture the multifaceted economic impact of migraine.
Introduction of Sumatriptan
Early examinations of the economic burden of migraine coincided
with the introduction of the ﬁrst triptan, sumatriptan, used for
treatment of acute migraine attacks. At the time, sumatriptan was
an exceptional drug in that it was expensive relative to existing
treatment, but also highly effective. This led to a newmethodology
for the evaluation of cost-effectiveness of migraine care, one that
was based upon a wider range of criteria than drug cost alone. In
particular, research began to examine the extent to which the
acquisition cost of a drug such as sumatriptan was offset by
reductions in both direct costs, such as overall health-care expen-
ditures, and indirect costs, such as productivity loss. For example,
Legg et al. evaluated the cost-effectiveness of sumatriptan by
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measuring health-care costs (emergency department [ED] visits,
physician ofﬁce visits, hospital visits, and medications) and
number of days without migraine-related disability before and
following treatment with sumatriptan [55]. In other randomized
controlled trials of sumatriptan, the average disability time per
treated attackwas approximately 2 hours, comparedwith 4 hours
in untreated patients. By evaluating disability-free time intervals
as a study end point, researchers attempted to establish a clearer
picture of the overall savings to society when sumatriptan became
available [55–57].
Introduction of other Triptan Drugs
As other triptans, such as rizatriptan, almotriptan, and eletrip-
tan, were developed and introduced, economic comparisons of
triptans were prepared. Some studies employed efﬁcacy data
from randomized clinical trials and combined this with an eco-
nomic analysis of drug cost. Other studies examined the addi-
tional costs associated with the triptan-associated adverse event
of chest pain. Meta-analyses of overall efﬁcacy and adverse event
proﬁles across multiple clinical trials were evaluated. Last, others
compared drug costs and aggregate numbers needed to treat in
an effort to assess the wide-ranging cost-effectiveness of triptans
[58–63]. Studies of the economic impact of acute treatments
continue [64], and the value of triptans continues to be compared
to nontriptan acute treatments [65].
The Costs of Medication Overuse and the Emergence
of Migraine Prophylaxis
By the late 1990s, both payers and clinicians began to be con-
cerned that triptans were being overused in the treatment of
acute migraine, and in the early 2000s, researchers in Europe
began studying medication-overuse headache (MOH). In a 2002
prospective study of 98 patients, Limmroth and colleagues found
that triptan overuse led to MOH more quickly and at lower dose
levels than did overuse of ergots or analgesics. They also found
that patients were more likely to describe a daily migraine-like
MOH with triptan overuse, as opposed to tension-type headache
with ergots and analgesics [66].
Two longitudinal, retrospective review studies of medical and
pharmacy claims in HMOs found that limits on monthly triptan
access reduced drug costs. Nevertheless, the two studies (con-
ducted in 1999 and 2003) had conﬂicting ﬁndings as to the effect
of these limits on other health-care resource costs, with the ﬁrst
study ﬁnding that additional migraine-related costs did not sig-
niﬁcantly change, and the second study ﬁnding reduced costs
[67,68]. Nevertheless, in one of the above-cited studies on
sumatriptan limitation, Goldfarb and colleagues noted that as
sumatriptan use was reduced, prescriptions for drugs that could
be used for migraine prevention increased by 33.9% [67].
Indeed, as early as the mid-1990s, the costs of various prophy-
lactic treatments for migraine began to be compared [69].
In part spurred by the concern about the possible over use of
triptans, there has been a focus on prophylactic treatment of
migraine. Current clinical guidelines for prophylactic treatment
are contained in Table 4. Following this clinical focus on prophy-
lactic treatment, a new body of research has emerged to examine
the economic impact of prophylactic treatment for migraine.
There is sufﬁcient evidence and consensus exists to recommend
topiramate, divalproex sodium, amitriptyline, timolol, and pro-
pranolol as effective ﬁrst-line agents for migraine prophylaxis
[70]. According to Silberstein and colleagues, migraine preventive
therapy is effective in reducing overall resource utilization, includ-
ing the use of other migraine medications and the frequency of
physician and emergency room visits [71].
It was not overlooked that the economic beneﬁts of costly
migraine treatments were likely to be greatest in patients with the
most severe disease. In 2002, Adelman and colleagues observed
that in patients responsive to acute medications, preventive
therapy was only cost-effective if the patient experienced a high
frequency of migraine or comorbid disease [72]. Brown and
colleagues found that the costs of topiramate for migraine pre-
vention could be offset by gains in reduced headache frequency,
disability hours, and lost productivity. Nevertheless, their cost-
effectiveness analysis modeled the use of topiramate for patients
with frequent (two or more per month) attacks or for patients
who experienced substantial disruption of daily activities
[71,73].
Although the threshold for prophylactic treatment of
migraine has remained relatively high, recent clinical ﬁndings
suggest that lowering this threshold may need to be considered.
This reconsideration of prophylactic treatment has important
implications for the standards of economic evaluation in
migraine and suggests that the need for a reassessment of the
standards of economic evaluation of migraine preventive therapy
may be necessary.
Long-Term Impact of Migraine and the Cost
of Prophylaxis
Recent clinical studies suggest that contrary to previous assump-
tions, migraine may be a progressive disease that potentially
leads to chronic headache conditions, impaired long-term psy-
chosocial functioning, and permanent neurologic damage. Epi-
demiologic studies have recently indicated that 4% to 5% of the
general population suffers from chronic daily headache (CDH),
which is characterized by 15 or more headache days per month,
and that transformed migraine—the transformation of episodic
migraine to the chronic form of the disorder—accounts for
approximately half of these patients. Although medication
overuse and baseline frequency of attacks explained some CDH,
a subgroup analysis indicated that migraine in and of itself was
potentially a progressive disorder [71,74].
In addition, evidence is accumulating, indicating that for
some migraineurs, repeated headache episodes may result in
permanent changes to central nervous system (CNS) structure or
function, in particular free radical formation, neuronal injury,
and iron deposition [75,76]. Migraine may also be a risk factor
for subclinical brain lesions. A Dutch population-based study
found a higher rate of posterior circulation infarcts and deep
white matter lesions among subjects aged 30 to 60 years with a
history of migraine compared with nonmigraine controls [77].
Nevertheless, the precise relationship of white matter lesions to
migraine is not yet known [75,77]. Repeated episodes of oligemia
during migraine aura have been suggested as the cause of subtle
Table 4 Clinical guidelines on the use of prophylactic treatment for
migraine
• Recurring migraine that signiﬁcantly interferes with daily routine despite
acute treatment
• 2 attacks per month producing disability and lasting three or more days
• Infrequent headache attacks producing profound disability
• Failure of, contraindication to, or troublesome side effects from acute
medications
• Overuse of acute medications
• Special circumstances (e.g., hemiplegic migraine, attacks with risk of
permanent neurological injury)
• Very frequent headaches (>2 per week) with rebound risk
• Patient preference, desire to have as few attacks as possible
Source: Silberstein, 2005 [71].
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neuronal damage to the visual system, and it has been suggested
that a similar mechanism may cause damage in the auditory
system [75,76].
Not only has migraine been implicated in causing permanent
changes to CNS structure and function, it has also been impli-
cated as a possible cause of cardiovascular and cerebrovascular
disease. In fact, migraine with aura has been shown to increase
the risk of major cardiovascular disease and stroke by twofold
[78]. It is generally accepted that physiological changes respon-
sible for head pain and aura associated with migraine are of
neurovascular origin. Similarly, the vasculature may play a role in
adverse cardiovascular events stemming from migraine. Potential
mechanisms for migrainous infarction include microcirculatory
vasoconstriction, intracerebral large vessel spasm, and vascular
changes because of cortical spreading depression. Stroke occur-
ring remote of the migraine attack is thought to be caused by
endothelial-related hypercoagulability, arterial dissection, and
cardioembolism. Endothelial dysfunction as a cause of or subse-
quent to migraine may have a role in ischemic heart disease [79].
Indeed, deleterious clinical outcomes associated with migraine
extend far beyond just symptoms of migraine attack.
In addition to the long-term physical effects of migraine,
clinical experience suggests that prolonged psychosocial impair-
ment because of headache is more likely among patients who
suffer from chronic forms of the disease, with social functioning
improvement often lagging behind migraine symptom improve-
ment [75].
Patients that experience migraine-like symptoms also experi-
ence substantial impairment. Patients with probable migraine,
deﬁned as a headache that meets all criteria except migraine with
or without aura, experience increased depression, increased dis-
ability, and reductions in HRQoL compared with those without
migraine. More importantly, decrements in these measures
because of probable migraine were similar to migraine. This
ﬁnding expands our current understanding and suggests that
probable migraine is a form of migraine, and should be consid-
ered when developing a treatment plan [3].
If conﬁrmed, these ﬁndings would suggest that early, aggres-
sive intervention for migraine prevention, targeted to reduce
headache frequency and/or severity, may reduce risk factors for
long-term CNS and vascular damage, as well as prevent the
progression of migraine to the more debilitating state of trans-
formed migraine [71,75]. Currently, most physicians do not
think of migraine as they do illnesses such as diabetes, hyper-
tension, asthma, or rheumatoid arthritis. Nevertheless, migraine
may need to be re-examined from a similar perspective, as a
chronic illness for which preventative therapy is important to
delay or reduce more serious forms or complications [75]. Simi-
larly, economic evaluations to date have focused on the cost-
effectiveness of migraine as an episodic rather than a chronic
and progressive disease. Should these more recent ﬁndings be
established, the standards of economic evaluation of migraine
will undoubtedly need to be re-envisioned once again to take
into account the long-term effects and costs of the disease.
Future Studies of Migraine
The traditional goal of prevention is to prevent headache attacks
and thereby limit the current pain and disability experienced by
headache sufferers. In the near term, we should additionally
assess the ability of migraine prevention to reduce the incidence
and associated costs of transformed migraine. In the longer term,
the value of prevention may be found to be in its ability to reduce
the incidence and associated costs of cardiovascular, cerebrovas-
cular, and long-term CNS damage consequent to frequent and
severe migraines. The economics of migraine prevention will
change as future studies more clearly deﬁne the burden of trans-
formed migraine as well as disease progression.
Conclusion
Despite its high prevalence and associated disability, migraine is
not generally perceived as a serious medical condition that
imposes a substantial burden upon society. Evidence suggests,
however, that the burden of migraine is substantial. Those who
carry that burden include patients and their families, employers,
and society. Economic evaluation of migraine treatment has gen-
erally responded to clinical developments. Current studies have
begun to suggest that migraine is a progressive disease that can
cause vascular and long-term CNS damage. If conﬁrmed, both
the treatment and economic evaluation of migraine may require
major reconsideration.
This study was sponsored by the National Headache Foundation through
a grant from Ortho-McNeil Neurologics, Inc.
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